Trials / Enrolling By Invitation
Enrolling By InvitationNCT05730582
Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening
- Status
- Enrolling By Invitation
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 500,000 (estimated)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study team's central hypothesis is that the Parkland Diabetes Detection Program (PDDP) screening invitations targeted by race/ethnicity with culturally concordant messaging and tailored by glycemic risk (known PDM vs. unknown glycemic state) plus phone-based navigation of non-responders will be more effective at closing screening gaps than PDDP generic screening invitations and usual care, opportunistic screening alone.
Detailed description
The research team will conduct a pragmatic, split cluster randomized controlled trial (clinic=cluster; patient randomization) in 12 community-based primary care clinics in an integrated safety net health system serving a high-risk, racially/ethnically diverse population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Parkland Diabetes Detection Program (PDDP) Screening Invitation | The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second "reminder" invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days. |
Timeline
- Start date
- 2024-03-05
- Primary completion
- 2026-12-01
- Completion
- 2028-12-30
- First posted
- 2023-02-16
- Last updated
- 2025-04-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05730582. Inclusion in this directory is not an endorsement.